Infectious Disease

Cat. No.

AT0458

CAS No.

1374419-41-6

Tosatoxumab

Synonyms: KBSA301; AR-301

Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody engineered to specifically neutralize the alpha-toxin (alpha-hemolysin; Hla) produced by Staphylococcus aureus. By targeting an N-terminal epitope of alpha-toxin, Tosatoxumab inhibits the oligomerization process essential for the formation of functional toxin pores. This antibody offers promising applications in passive immunotherapy for Staphylococcus aureus pneumonia, serving as an adjunctive treatment alongside standard antibiotic therapies.

Cat. No.

AT0462

CAS No.

2135632-36-7

Maftivimab

Synonyms: REGN3470-3471-3479

Maftivimab (REGN3470-3471-3479), also known as Atoltivimab and Odesivimab under the brand name Inmazeb, is an FDA-approved monoclonal antibody cocktail designed to inhibit Filovirus activity. This biologic is specifically targeted against the Zaire ebolavirus, making it highly relevant for research focused on this pathogen. Maftivimab is utilized in studies investigating the mechanisms of viral entry and replication, as well as in the development of therapeutic strategies for Ebola virus infection.

Cat. No.

AT0483

CAS No.

2135632-30-1

Odesivimab

Synonyms: REGN-3471

Odesivimab is a human monoclonal antibody specifically designed to target the glycoprotein of the Ebola virus. It exhibits a high affinity for the recombinant histidine-tagged Makona strain Ebola virus glycoprotein ectodomain, with a dissociation constant (K_D) of 7.74 nM. This antibody is ideal for use in research focused on Ebola virus infection, aiding in the study of viral entry mechanisms and immune response.

Cat. No.

AT0503

CAS No.

2101210-43-7

Elipovimab

Elipovimab is a potent, broadly neutralizing antibody designed for the targeted elimination of cells infected with HIV-1. This antibody binds specifically to the HIV-1 envelope protein, facilitating the recognition and destruction of infected cells by the immune system. Elipovimab's broad neutralizing capability makes it a valuable tool for research into the mechanisms of HIV infection and potential therapeutic interventions.

Cat. No.

AT0526

CAS No.

2419087-87-7

Zamerovimab

Synonyms: CTB011

Zamerovimab (CTB011) is a humanized IgG1κ monoclonal antibody designed to specifically bind to non-overlapping epitopes on the rabies virus (RABV) glycoprotein, focusing on residues at and near antigenic site III. This targeted binding capability makes Zamerovimab an essential tool for research in rabies, facilitating detailed studies on viral mechanisms and potential therapeutic interventions.

Cat. No.

AT0558

CAS No.

569658-79-3

Libivirumab

Synonyms: 17.1.41

Libivirumab (17.1.41) is a human monoclonal antibody targeting the hepatitis B virus (HBV). It exhibits potent neutralizing activity against HBV surface antigen (HBsAg) and HBV e antigen (HBeAg), with half-maximal inhibitory concentrations (IC50) of 35 ng/mL and 130 ng/mL, respectively. This antibody is designed for use in research studies aimed at understanding HBV pathogenesis and for the development of therapeutic strategies against HBV infections.

Cat. No.

AT0563

Anti-HIV gp120 Antibody (55-36)

The Anti-HIV gp120 Antibody (55-36) is a chimeric mouse monoclonal antibody of the IgG1κ subtype designed specifically to target the HIV gp120 glycoprotein. This antibody serves as a crucial tool in the study of HIV infection mechanisms and the development of therapeutic strategies. For accurate experimental control, it is recommended to use Mouse IgG1 kappa Isotype Control with this antibody.

Cat. No.

AT0573

CAS No.

1443004-16-7

Navivumab

Synonyms: CT-P23

Navivumab (CT-P23) is a monoclonal antibody targeting the hemagglutinin (HA) of influenza A virus. It specifically binds to the stem fusion domain in HA2, effectively neutralizing H1, H2, H5, and H9 subtypes of influenza A viruses. This antibody is crucial for studies focused on viral entry mechanisms and the development of broad-spectrum antiviral therapies.

Cat. No.

AT0574

CAS No.

3023741-03-6

Retavibart

Retavibart is a recombinant human respiratory syncytial virus (RSV) fusion glycoprotein F, designed for use in antiviral research. This product serves as a critical tool in the study of viral entry and fusion mechanisms of RSV. The isotype of Retavibart is Human IgG1 kappa, making it suitable for a variety of experimental setups requiring this specific control.

Cat. No.

AT0576

CAS No.

2599039-60-6

Ogalvibart

Synonyms: C-135-LS; BMS-986414

Ogalvibart (C-135-LS) is a human monoclonal antibody of the IgG1 subtype, specifically designed to target the SARS-CoV-2 virus. It exhibits high affinity binding to the receptor-binding domain (RBD) of the spike (S) glycoprotein on the virus surface. When used in conjunction with C144LS at a 1:1 ratio, Ogalvibart demonstrates significant preventive efficacy, effectively inhibiting the progression of COVID-19 in a rhesus monkey model. This antibody is pivotal for research focused on the mechanisms of SARS-CoV-2 infection and the development of therapeutic strategies.

Cat. No.

AT0580

CAS No.

2640223-84-1

Masavibart

Synonyms: ZRC3308-A7

Masavibart (ZRC3308-A7) is a monoclonal antibody of the IgG1 subtype, specifically designed to target SARS-CoV-2. This antibody exhibits strong binding affinity to a distinct, non-competing epitope located on the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. For enhanced therapeutic efficacy, Masavibart can be co-administered with ZRC3308-B10 in a 1:1 ratio. This combination has shown potential in the prevention of COVID-19, particularly effective in the initial stages of the disease, prior to the onset of severe symptoms.

Cat. No.

AT0586

CAS No.

2599039-61-7

Crexavibart

Synonyms: BMS-986413; C-144-LS

Crexavibart (BMS-986413; C-144-LS) is an IgG1λ2 monoclonal antibody specifically designed to target the receptor-binding domain of the SARS-CoV-2 spike (S) glycoprotein. This antibody binds with high specificity and affinity, making it a valuable tool for research focused on viral entry mechanisms, neutralization assays, and therapeutic intervention studies related to COVID-19.

Cat. No.

AT0593

CAS No.

2769699-23-0

Sonavibart

Sonavibart is a human monoclonal antibody of the IgG1κ subtype that specifically targets the hemagglutinin HA protein of influenza A virus. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

Cat. No.

AT0602

CAS No.

2375952-29-5

Ansuvimab

Synonyms: Ansuvimab-zyk; mAb114

Ansuvimab-zyk is a recombinant human monoclonal IgG1 antibody designed to target and neutralize Zaire ebolavirus. It functions by specifically binding to the viral glycoprotein, thereby inhibiting the virus's ability to enter and infect host cells. This interaction is crucial for preventing the spread of infection and is a key mechanism in its antiviral efficacy against Zaire ebolavirus.

Cat. No.

AT0624

CAS No.

1792982-57-0

Cosfroviximab

Synonyms: c13C6-FR1

Cosfroviximab (c13C6-FR1) is a chimeric monoclonal antibody derived from both mouse and human sources, designed to target the glycoprotein of the Ebola virus (EBOV-GP). This antibody is specifically engineered for high specificity and affinity towards EBOV-GP, making it an essential tool for research into the pathogenesis and potential treatments of Ebola virus infections.

Cat. No.

AT0643

CAS No.

138660-96-5

Sevirumab

Synonyms: MSL-109

Sevirumab (MSL-109) is a human IgG1 monoclonal antibody designed to neutralize cytomegalovirus (CMV). This antibody specifically targets CMV glycoprotein H (gH) complexes, effectively inhibiting viral replication. It demonstrates potent antiviral activity with an EC50 value of 0.3 μg/mL, making it a valuable tool for research into CMV pathogenesis and therapeutic intervention.

Cat. No.

AT0646

CAS No.

1351470-16-0

Pritoxaximab

Pritoxaximab is a monoclonal antibody of the IgG1κ isotype designed to specifically target and neutralize Shiga toxin type 1. This antibody serves as a crucial tool in the study of bacterial pathogenesis and can be applied in research focused on the therapeutic intervention of diseases caused by Shiga toxin-producing bacteria.

Cat. No.

AT0665

CAS No.

1629620-18-3

Suvratoxumab

Synonyms: MEDI4893

Suvratoxumab (MEDI4893) is a high-affinity, long-acting human monoclonal antibody of the IgG1κ subtype, designed to target and neutralize α-toxin, a critical virulence factor of Staphylococcus aureus. This antibody has demonstrated efficacy in enhancing survival rates and reducing pulmonary damage in immunocompromised mouse models of pneumonia. Additionally, Suvratoxumab has been shown to augment the antibacterial effects of antibiotics such as Vancomycin and Linezolid, suggesting its potential utility in synergistic therapeutic strategies against S. aureus infections.

Cat. No.

AT0668

CAS No.

2429913-18-6

Clesrovimab

Synonyms: MK1654

Clesrovimab (MK1654) is a fully human monoclonal antibody that specifically targets the respiratory syncytial virus (RSV) fusion (F) glycoprotein. This antibody holds significant potential for use in research focused on respiratory syncytial virus infections, facilitating studies aimed at understanding viral mechanisms and developing therapeutic strategies.

Cat. No.

AT0681

CAS No.

2851892-98-1

Lotivibart

Lotivibart is a human monoclonal antibody of the IgG1κ subtype designed to specifically target the gp120 envelope glycoprotein. For experimental control purposes, the recommended isotype control is Human IgG1 kappa Isotype Control.

Cat. No.

AT0706

CAS No.

2043950-09-8

VIS-410

VIS-410 is a fully human monoclonal antibody of the IgG1 subclass that specifically targets the influenza A virus. For experimental control purposes, the recommended isotype control is Human IgG1 kappa, Isotype Control. This antibody is designed for use in research studies aimed at understanding and potentially mitigating the impact of influenza A infections.

Cat. No.

AT0708

CAS No.

762260-74-2

Efungumab

Efungumab is a monoclonal antibody characterized by its potent antifungal properties. This antibody specifically targets and binds to Heat Shock Protein 90 (HSP 90), a critical component in fungal cell viability. By binding to this protein, Efungumab inhibits a necessary conformational change, thereby compromising fungal cell survival. This mechanism of action makes Efungumab an invaluable tool for research focused on invasive candidiasis (IC), providing insights into fungal pathogenesis and potential therapeutic interventions.

Cat. No.

AT0716

CAS No.

2420564-02-7

Tixagevimab

Synonyms: AZD8895

Tixagevimab (AZD8895) is a human monoclonal antibody designed to target the receptor binding domain (RBD) of SARS-CoV-2. It effectively neutralizes the virus by binding to the RBD as well as the S-glycoprotein ectodomain, thereby inhibiting the S-glycoprotein-mediated attachment to the host cell receptor. This antibody is pivotal for research focused on the mechanisms of viral entry and the development of therapeutic strategies against SARS-CoV-2.

Cat. No.

AT0735

CAS No.

1422526-93-9

CR-8020

CR-8020 is a human IgG1 monoclonal antibody designed to specifically target the H3N2 subtype of influenza A virus. This antibody recognizes and binds to the hemagglutinin (HA) protein of H3N2 strains, demonstrating potent inhibitory concentrations (IC50) of 3.36 nM and 0.06 nM against A/Brisbane/10/2007 and A/Wyoming/3/2003 strains, respectively. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended. CR-8020 serves as a valuable tool for research focused on the immunological response to H3N2 infections and the development of therapeutic strategies against influenza A.

Cat. No.

AT0742

Nisfevitug

Nisfevitug is a human IgG1 κ monoclonal antibody specifically targeting the SARS-CoV-2 virus. For accurate experimental control, it is recommended to use Human IgG1 kappa Isotype Control.